国际眼科杂志
國際眼科雜誌
국제안과잡지
International Eye Science
2015年
10期
1778-1781
,共4页
翟改霞%姜涛%赵善瑶%王文营%王云霄
翟改霞%薑濤%趙善瑤%王文營%王雲霄
적개하%강도%조선요%왕문영%왕운소
雷珠单抗%视网膜中央静脉阻塞%黄斑水肿%血管内皮生长因子%有效性%安全性
雷珠單抗%視網膜中央靜脈阻塞%黃斑水腫%血管內皮生長因子%有效性%安全性
뢰주단항%시망막중앙정맥조새%황반수종%혈관내피생장인자%유효성%안전성
ranibizumab%central retinal vein occlusion%macular edema%vascular endothelial growth factor%efficacy%safety
目的：观察雷珠单抗对视网膜中央静脉阻塞( central retinal vein occlusion,CRVO )继发黄斑水肿治疗的有效性和安全性。<br> 方法：根据标准将入组的24例视网膜中央静脉阻塞继发黄斑水肿患者,年龄30~70(平均51.58±10.32)岁,双盲随机分配到组玉和组Ⅱ。组玉前3mo,每月1次0.5mg雷珠单抗玻璃体腔注射并给予复方血栓通胶囊药物,组Ⅱ前3 mo仅给予复方血栓通胶囊药物。组玉和组Ⅱ从第3 mo起均开始雷珠单抗,PRN( Prore nata)治疗。两组治疗前最佳矫正视力( best-corrected visual acuity,BCVA)及中心视网膜厚度( central retinal thickness,CRT)比较差异无统计学意义( P>0.05)。统计分析两组治疗期间的 BCVA、CRT、实验室检查结果、眼部及全身不良反应。<br> 结果：组玉治疗前最佳矫正视力( BCVA )为52.67±1.78,治疗1wk,1、2、3、4、6、12mo的BCVA分别为63.67±1.61、66.25±1.60、69.58±1.68、70.75±5.22、65.58±4.34、68.92±3.4、70.17±3.7,与治疗前比较有显著统计学差异(P<0.05),组玉治疗前 CRT 为539.00±10.94μm,治疗1wk,1、2、3、4、6、12mo 的 CRT 分别是326.67±20.83、264.58±17.11、232.00±13.04、231.25±78.68、316.00±172.48、218.00±105.25、220.58±33.43μm,与治疗前比较有显著统计学差异(P<0.05),组Ⅱ治疗前BCVA为52.25±2.83,CRT为539.92±12.21μm,组Ⅱ治疗3mo BCVA 为57.08±3.12,与组玉治疗3mo BCVA比较有统计学差异( P<0.05),组Ⅱ治疗3mo CRT为497.92±11.91μm,与组玉治疗3mo CRT比较有统计学差异(P<0.05),治疗访视过程中未发现眼部及全身明显不良反应。<br> 结论：玻璃体腔注射雷珠单抗能在短期内能减轻黄斑水肿并提高视力,减少黄斑区荧光渗漏,但在眼内作用的持续时间短,需反复注射。雷珠单抗在CRVO继发黄斑水肿的治疗中具有很好的有效性和安全性。
目的：觀察雷珠單抗對視網膜中央靜脈阻塞( central retinal vein occlusion,CRVO )繼髮黃斑水腫治療的有效性和安全性。<br> 方法：根據標準將入組的24例視網膜中央靜脈阻塞繼髮黃斑水腫患者,年齡30~70(平均51.58±10.32)歲,雙盲隨機分配到組玉和組Ⅱ。組玉前3mo,每月1次0.5mg雷珠單抗玻璃體腔註射併給予複方血栓通膠囊藥物,組Ⅱ前3 mo僅給予複方血栓通膠囊藥物。組玉和組Ⅱ從第3 mo起均開始雷珠單抗,PRN( Prore nata)治療。兩組治療前最佳矯正視力( best-corrected visual acuity,BCVA)及中心視網膜厚度( central retinal thickness,CRT)比較差異無統計學意義( P>0.05)。統計分析兩組治療期間的 BCVA、CRT、實驗室檢查結果、眼部及全身不良反應。<br> 結果：組玉治療前最佳矯正視力( BCVA )為52.67±1.78,治療1wk,1、2、3、4、6、12mo的BCVA分彆為63.67±1.61、66.25±1.60、69.58±1.68、70.75±5.22、65.58±4.34、68.92±3.4、70.17±3.7,與治療前比較有顯著統計學差異(P<0.05),組玉治療前 CRT 為539.00±10.94μm,治療1wk,1、2、3、4、6、12mo 的 CRT 分彆是326.67±20.83、264.58±17.11、232.00±13.04、231.25±78.68、316.00±172.48、218.00±105.25、220.58±33.43μm,與治療前比較有顯著統計學差異(P<0.05),組Ⅱ治療前BCVA為52.25±2.83,CRT為539.92±12.21μm,組Ⅱ治療3mo BCVA 為57.08±3.12,與組玉治療3mo BCVA比較有統計學差異( P<0.05),組Ⅱ治療3mo CRT為497.92±11.91μm,與組玉治療3mo CRT比較有統計學差異(P<0.05),治療訪視過程中未髮現眼部及全身明顯不良反應。<br> 結論：玻璃體腔註射雷珠單抗能在短期內能減輕黃斑水腫併提高視力,減少黃斑區熒光滲漏,但在眼內作用的持續時間短,需反複註射。雷珠單抗在CRVO繼髮黃斑水腫的治療中具有很好的有效性和安全性。
목적：관찰뢰주단항대시망막중앙정맥조새( central retinal vein occlusion,CRVO )계발황반수종치료적유효성화안전성。<br> 방법：근거표준장입조적24례시망막중앙정맥조새계발황반수종환자,년령30~70(평균51.58±10.32)세,쌍맹수궤분배도조옥화조Ⅱ。조옥전3mo,매월1차0.5mg뢰주단항파리체강주사병급여복방혈전통효낭약물,조Ⅱ전3 mo부급여복방혈전통효낭약물。조옥화조Ⅱ종제3 mo기균개시뢰주단항,PRN( Prore nata)치료。량조치료전최가교정시력( best-corrected visual acuity,BCVA)급중심시망막후도( central retinal thickness,CRT)비교차이무통계학의의( P>0.05)。통계분석량조치료기간적 BCVA、CRT、실험실검사결과、안부급전신불량반응。<br> 결과：조옥치료전최가교정시력( BCVA )위52.67±1.78,치료1wk,1、2、3、4、6、12mo적BCVA분별위63.67±1.61、66.25±1.60、69.58±1.68、70.75±5.22、65.58±4.34、68.92±3.4、70.17±3.7,여치료전비교유현저통계학차이(P<0.05),조옥치료전 CRT 위539.00±10.94μm,치료1wk,1、2、3、4、6、12mo 적 CRT 분별시326.67±20.83、264.58±17.11、232.00±13.04、231.25±78.68、316.00±172.48、218.00±105.25、220.58±33.43μm,여치료전비교유현저통계학차이(P<0.05),조Ⅱ치료전BCVA위52.25±2.83,CRT위539.92±12.21μm,조Ⅱ치료3mo BCVA 위57.08±3.12,여조옥치료3mo BCVA비교유통계학차이( P<0.05),조Ⅱ치료3mo CRT위497.92±11.91μm,여조옥치료3mo CRT비교유통계학차이(P<0.05),치료방시과정중미발현안부급전신명현불량반응。<br> 결론：파리체강주사뢰주단항능재단기내능감경황반수종병제고시력,감소황반구형광삼루,단재안내작용적지속시간단,수반복주사。뢰주단항재CRVO계발황반수종적치료중구유흔호적유효성화안전성。
AIM:To observe the efficacy and safety of intravitreal injection of Ranibizumab in the treatment of macular edema secondary to central retinal vein occlusion ( CRVO) . <br> METHODS:According to the standard, 24 patients with macular edema secondary to CRVO were double-blind randomized to groupⅠand groupII. They were aged 30~70 years old, average (51. 58±10. 32) years. Patients of groupⅠ were treated with intravitreal injection of 0. 5mg ranibizumab monthly for the first three months and given compound thrombosis capsule. Compared with groupⅠ, patients of group II were only given compound thrombosis capsule. Subjects of two groups use PRN ( Pro re nata ) therapy with ranibizumab from the third month. No significant difference was found between the two groups in the best-corrected visual acuity ( BCVA ) and central retinal thickness ( CRT ) before the treatment (P>0. 05). BCVA, CRT, laboratory results and ocular and systemic adverse reactions of the two groups during treatment were conducted and statistically analyzed. <br> RESULTS: BCVA of group Ⅰ was 52. 67±1. 78 before treatment, and BCVA were respectively 63. 67±1. 61, 66. 25±1. 60, 69. 58±1. 68, 70. 75±5. 22, 65. 58±4. 34, 68. 92±3. 4, 70.17±3. 7 at 1wk, 1, 2, 3, 4, 6, and 12mo after treatment with significant difference compared with before injections (P<0. 05). CRT of group Ⅰ was 539. 00±10. 94μm before the treatment, and that were respectively 326. 67±20. 83, 264. 58±17. 11, 232. 00±13. 04, 231. 25±78. 68, 316. 00±172.48, 218. 00±105. 25, 220. 58±33. 43μm at 1wk, 1, 2, 3, 4, 6, and 12mo after treatment with significant difference compared with before injections ( P< 0. 05 ). BCVA of group II was 52. 25±2. 83 and CRT was 539. 92±12. 21μm, BCVA of group II was 57. 08±3. 12μm 3mo after treatment and significant difference was found compared with group玉3mo after treatment (P<0. 05). CRT of group II was 497. 92 ± 11.91μm 3mo after treatment and significant difference was found compared with group Ⅰ 3mo after treatment ( P < 0. 05 ). Ocular and systemic obviously adverse reactions were not found during treatment. <br> CONCLUSION: Intravitreal injection of ranibizumab contributes to relieving macular edema, improving visual acuity and reducing fluorescence leakage of macular area in short - term. But patients need repeated injection. Ranibizumab is effectiveness and safety in the treatment of macular secondary to CRVO.
